.

Deeper Knowledge, Faster

  • Anticipate your formulary budget
  • Analyze global market entry opportunities
  • Identify first generic entrants

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Cantor Fitzgerald
US Department of Justice
Merck
Fish and Richardson
Federal Trade Commission
Medtronic
Citi
Queensland Health

Generated: June 23, 2017

DrugPatentWatch Database Preview

Fludarabine phosphate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for fludarabine phosphate and what is the scope of fludarabine phosphate patent protection?

Fludarabine phosphate
is the generic ingredient in three branded drugs marketed by Actavis Totowa, Mustafa Nevzat Ilac, Sandoz, Genzyme Corp, Actavis Llc, Fresenius Kabi Usa, Mylan Labs Ltd, Sagent Pharms, Sanofi Aventis Us, and Hospira, and is included in thirteen NDAs. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Fludarabine phosphate has sixty-four patent family members in thirty-four countries.

There are ten drug master file entries for fludarabine phosphate. Nine suppliers are listed for this compound.

Summary for Generic Name: fludarabine phosphate

Tradenames:3
Patents:3
Applicants:10
NDAs:13
Drug Master File Entries: see list10
Suppliers / Packagers: see list9
Bulk Api Vendors: see list48
Clinical Trials: see list1,538
Patent Applications: see list5,877
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:fludarabine phosphate at DailyMed

Pharmacology for Ingredient: fludarabine phosphate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hospira
FLUDARABINE PHOSPHATE
fludarabine phosphate
INJECTABLE;INJECTION077790-001Apr 6, 2007APRXNoYes► Subscribe► Subscribe
Genzyme Corp
FLUDARA
fludarabine phosphate
INJECTABLE;INJECTION020038-001Apr 18, 1991DISCNYesNo► Subscribe► Subscribe
Fresenius Kabi Usa
FLUDARABINE PHOSPHATE
fludarabine phosphate
INJECTABLE;INJECTION078393-001Oct 15, 2007APRXNoYes► Subscribe► Subscribe
Actavis Totowa
FLUDARABINE PHOSPHATE
fludarabine phosphate
INJECTABLE;INJECTION078610-001Feb 11, 2009APRXNoNo► Subscribe► Subscribe
Fresenius Kabi Usa
FLUDARABINE PHOSPHATE
fludarabine phosphate
INJECTABLE;INJECTION078544-001Oct 15, 2007APRXNoNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: fludarabine phosphate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Genzyme Corp
FLUDARA
fludarabine phosphate
INJECTABLE;INJECTION020038-001Apr 18, 19914,357,324*PED► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: fludarabine phosphate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,046,322 Process for the production of fludarabine-phosphate lithium, sodium, potassium, calcium and magnesium salts and purification process for the production of fludarabine-phosphate and fludarabine-phosphate with a purity of at least 99.5%► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: fludarabine phosphate

Country Document Number Estimated Expiration
Hong Kong1033831► Subscribe
Australia2002349043► Subscribe
Poland341659► Subscribe
Australia739574► Subscribe
European Patent Office1455760► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Moodys
Fish and Richardson
AstraZeneca
McKesson
Chubb
QuintilesIMS
Mallinckrodt
Medtronic
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot